An updated patent review of glutaminase inhibitors (2019–2022)

References

• DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv 2016 May;2. 5
   Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of Cancer: the next generation. Cell. 2011 Mar;144(5):646–674.
   PubMed Web of Science ®Google Scholar
• Ward PS, Thompson CB. Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell. 2012 Mar;21(3):297–308.
   PubMed Web of Science ®Google Scholar
• Heiden MGV, Cantley LC, Thompson CB. Understanding the Warburg Effect: the Metabolic Requirements of Cell Proliferation. Science. 2009 May;324(5930):1029–1033.
   PubMed Web of Science ®Google Scholar
• Koppenol WH, Bounds PL, Dang CV. Otto Warburg’s contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011 May;11(5):325–337.
   PubMed Web of Science ®Google Scholar
• Warburg O. On the origin of cancer cells.Science. 1956 [1956 Feb];123(3191):309–314.
   PubMed Web of Science ®Google Scholar
• Reinfeld BI, Madden MZ, Wolf MM, et al. Cell-programmed nutrient partitioning in the tumour microenvironment. Nature. 2021 May;593(7858):282.
   PubMed Web of Science ®Google Scholar
• Altman BJ, Stine ZE, Dang CV. From Krebs to clinic: glutamine metabolism to cancer therapy. Nat Rev Cancer. 2016 Oct;16(10):619–634.
   PubMed Web of Science ®Google Scholar
• DeBerardinis RJ, Mancuso A, Daikhin E, et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. P Nat Acad Sci. 2007 Dec;104(49):19345–19350.
   PubMed Web of Science ®Google Scholar
• Hensley CT, Wasti AT, DeBerardinis RJ. Glutamine and cancer: cell biology, physiology, and clinical opportunities. J Clin Investig. 2013 Sep;123(9):3678–3684.
   PubMed Web of Science ®Google Scholar
• Sullivan LB, Gui DY, Hosios AM, et al. Supporting aspartate biosynthesis is an essential function of respiration in proliferating cells. Cell. 2015 Jul;162(3):552–563.
   PubMed Web of Science ®Google Scholar
• Yang CD, Ko B, Hensley CT, et al. Glutamine oxidation maintains the TCA cycle and cell survival during impaired mitochondrial pyruvate transport. Mol Cell. 2014 Nov;56(3):414–424.
   PubMed Web of Science ®Google Scholar
• Sainero-Alcolado L, Liano-Pons J, Ruiz-Perez MV, et al. Targeting mitochondrial metabolism for precision medicine in cancer. Cell Death Differ. 2022 Jul;29(7):1304–1317.
   PubMed Web of Science ®Google Scholar
• Godwin AK, Meister A, Odwyer PJ, et al. HIGH-RESISTANCE TO CISPLATIN IN HUMAN OVARIAN-CANCER CELL-LINES IS ASSOCIATED WITH MARKED INCREASE OF GLUTATHIONE SYNTHESIS. P Nat Acad Sci. 1992 Apr;89(7):3070–3074.
   PubMed Web of Science ®Google Scholar
• Choi CH, Ganji S, Hulsey K, et al. A comparative study of short- and long-TE H-1 MRS at 3 T for in vivo detection of 2-hydroxyglutarate in brain tumors. NMR Biomed. 2013 Oct;26(10):1242–1250.
   PubMed Web of Science ®Google Scholar
• Kelloff G, Hoffman JM, Johnson B, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res. 2005 Apr;11(8):2785–2808.
   PubMed Web of Science ®Google Scholar
• Lieberman BP, Ploessl K, Wang L, et al. PET Imaging of Glutaminolysis in Tumors by F-18-(2S,4R)4-Fluoroglutamine. J Nucl Med. 2011 Dec 1;52(12):1947–1955.
   PubMed Web of Science ®Google Scholar
• Doucey MA, Carrara S. Nanowire Sensors in Cancer. Trends Biotechnol. 2019 Jan;37(1):86–99.
   PubMed Web of Science ®Google Scholar
• Aledo JC, Gomez-Fabre PM, Olalla L, et al. Identification of two human glutaminase loci and tissue-specific expression of the two related genes. Mamm Genome. 2000 Dec;11(12):1107–1110.
   PubMed Web of Science ®Google Scholar
• Katt WP, Lukey MJ, Cerione RA. A tale of two glutaminases: homologous enzymes with distinct roles in tumorigenesis. Future Med Chem. 2017 Jan;9(2):223–243.
   PubMed Web of Science ®Google Scholar
• Elgadi KM, Meguid RA, Qian M, et al. Cloning and analysis of unique human glutaminase isoforms generated by tissue-specific alternative splicing. Physiol Genomics. 1999 Aug;1(2):51–62.
   PubMed Web of Science ®Google Scholar
• Cassago A, Ferreira APS, Ferreira IM, et al. Mitochondrial localization and structure-based phosphate activation mechanism of Glutaminase C with implications for cancer metabolism. P Nat Acad Sci. 2012 Jan;109(4):1092–1097.
   PubMed Web of Science ®Google Scholar
• Gao P, Tchernyshyov I, Chang TC, et al. c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolism. Nature. 2009 Apr;458(7239):762–U100.
   PubMed Web of Science ®Google Scholar
• Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. P Nat Acad Sci. 2008 Dec;105(48):18782–18787.
   PubMed Web of Science ®Google Scholar
• Sebastian C, Zwaans BMM, Silberman DM, et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell. 2012 Dec;151(6):1185–1199.
   PubMed Web of Science ®Google Scholar
• Rathore MG, Saumet A, Rossi JF, et al. The NF-kappa B member p65 controls glutamine metabolism through miR-23a. Int J Biochem Cell Biol. 2012 Sep;44(9):1448–1456.
   PubMed Web of Science ®Google Scholar
• Lukey MJ, Greene KS, Erickson JW, et al. The oncogenic transcription factor c-Jun regulates glutaminase expression and sensitizes cells to glutaminase-targeted therapy. Nat Commun. 2016;7:11321. DOI:10.1038/ncomms11321. https://www.nature.com/articles/ncomms11321
   PubMed Web of Science ®Google Scholar
• McGuirk S, Gravel S-P, Deblois G, et al. PGC-1alpha supports glutamine metabolism in breast cancer. Cancer Metab. 2013 2013 Dec;1(1):22.
   PubMedGoogle Scholar
• Reynolds MR, Lane AN, Robertson B, et al. Control of glutamine metabolism by the tumor suppressor Rb. Oncogene. 2014 Jan;33(5):556–566.
   PubMed Web of Science ®Google Scholar
• Gross MI, Demo SD, Dennison JB, et al. Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast Cancer. Mol Cancer Ther. 2014 Apr;13(4):890–901.
   PubMed Web of Science ®Google Scholar
• Wang J-B, Erickson JW, Fuji R, et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell. 2010 Sep 14;18(3):207–219.
   PubMed Web of Science ®Google Scholar
• Hernandez-Davies JE, Tran TQ, Reid MA, et al. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence. J Transl Med. 2015 Jun;13:13.
   PubMed Web of Science ®Google Scholar
• Roy S, Maity P. Modulation of metastatic potential of B16F10 melanoma cells by acivicin: synergistic action of glutaminase and Potentiation of cisplatin cytotoxicity. Asian Pac J Cancer Prev. 2007 Apr-Jun;8(2):301–306.
   PubMed Web of Science ®Google Scholar
• Gameiro PA, Yang JJ, Metelo AM, et al. In Vivo HIF-mediated reductive carboxylation is regulated by citrate levels and sensitizes VHL-deficient cells to glutamine deprivation. Cell Metab. 2013 Mar;17(3):372–385.
   PubMed Web of Science ®Google Scholar
• Shroff EH, Eberlin LS, Dang VM, et al. MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism. P Nat Acad Sci. 2015 May;112(21):6539–6544.
   PubMed Web of Science ®Google Scholar
• Emadi A, Ju SA, Tsukamoto T, et al. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol. 2014 Apr;42(4):247–251.
   PubMed Web of Science ®Google Scholar
• Seltzer MJ, Bennett BD, Joshi AD, et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res. 2010 Nov;70(22):8981–8987.
   PubMed Web of Science ®Google Scholar
• Willems L, Jacque N, Jacquel A, et al. Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia. Blood. 2013 Nov;122(20):3521–3532.
   PubMed Web of Science ®Google Scholar
• Huang F, Zhang QY, Ma H, et al. Expression of glutaminase is upregulated in colorectal cancer and of clinical significance. Int J Clin Exp Pathol. 2014;7(3):1093–1100.
   PubMed Web of Science ®Google Scholar
• Pieter A, van den Heuvel J, Jing J, et al. Analysis of glutamine dependency in non-small cell lung cancer GLS1 splice variant GAC is essential for cancer cell growth. Cancer Biol Ther. 2012 Oct;13(12):1185–1194.
   PubMed Web of Science ®Google Scholar
• Son J, Lyssiotis CA, Ying H, et al. Glutamine supports pancreatic cancer growth through a KRAS-regulated metabolic pathway. Nature. 2013 Apr;496(7443):101–+.
   PubMed Web of Science ®Google Scholar
• ChungBok MI, Vincent N, Jhala U, et al. Rat hepatic glutaminase: identification of the full coding sequence and characterization of a functional promoter. Biochem J. 1997 May;324(1):193–200.
   PubMedGoogle Scholar
• Gomez-Fabre PM, Aledo JC, Del Castillo-Olivares A, et al. Molecular cloning, sequencing and expression studies of the human breast cancer cell glutaminase. Biochem J. 2000 Jan;345(2):365–375.
   PubMedGoogle Scholar
• Suzuki S, Tanaka T, Poyurovsky MV, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. P Nat Acad Sci. 2010 Apr;107(16):7461–7466.
   PubMed Web of Science ®Google Scholar
• Xiao DB, Ren P, Su HX, et al. Myc promotes glutaminolysis in human neuroblastoma through direct activation of glutaminase 2. Oncotarget. 2015 Dec;6(38):40655–40666.
   PubMedGoogle Scholar
• Cline MS, Craft B, Swatloski T, et al. Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser. Sci Rep. 2013 Oct;3:2652. DOI:10.1038/srep02652.
   PubMed Web of Science ®Google Scholar
• Weinstein JN, Collisson EA, Mills GB, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013 Oct;45(10):1113–1120.
   PubMed Web of Science ®Google Scholar
• Lee YZ, Yang CW, Chang HY, et al. Discovery of selective inhibitors of Glutaminase-2, which inhibit mTORC1, activate autophagy and inhibit proliferation in cancer cells. Oncotarget. 2014 Aug;5(15):6087–6101.
   PubMedGoogle Scholar
• Martin-Rufian M, Nascimento-Gomes R, Higuero A, et al. Both GLS silencing and GLS2 overexpression synergize with oxidative stress against proliferation of glioma cells. J Mol Med. 2014 Mar;92(3):277–290.
   PubMed Web of Science ®Google Scholar
• Szeliga M, Obara-Michlewska M, Matyja E, et al. Transfection with liver-type glutaminase cDNA alters gene expression and reduces survival, migration and proliferation of T98G Glioma Cells. Glia. 2009 Jul;57(9):1014–1023.
   PubMed Web of Science ®Google Scholar
• Szeliga M, Zgrzywa A, Obara-Michlewska M, et al. Transfection of a human glioblastoma cell line with liver-type glutaminase (LGA) down-regulates the expression of DNA-repair gene MGMT and sensitizes the cells to alkylating agents. J Neurochem. 2012 Nov;123(3):428–436.
   PubMed Web of Science ®Google Scholar
• Xiang LS, Xie GF, Liu C, et al. Knock-down of glutaminase 2 expression decreases glutathione, NADH, and sensitizes cervical cancer to ionizing radiation. Biochim Biophys Acta Mol Cell Res. 2013 Dec;1833(12):2996–3005.
   Web of Science ®Google Scholar
• Wang S, Yan Y, Xu W-J, et al. The Role of Glutamine and Glutaminase in Pulmonary Hypertension. Front Cardiovasc Med. 2022Mar;2:9. DOI:10.3389/fcvm.2022.838657.
   Google Scholar
• Lien EC, Lyssiotis CA, Juvekar A, et al. Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer. Nat Cell Biol. 2016 May;18(5):572–+.
   PubMed Web of Science ®Google Scholar
• Halama A, Kulinski M, Dib SS, et al. Accelerated lipid catabolism and autophagy are cancer survival mechanisms under inhibited glutaminolysis. Cancer Lett. 2018;430:133–147.
   PubMed Web of Science ®Google Scholar
• Achkar IW, Kader S, Dib SS, et al. Metabolic Signatures of Tumor Responses to Doxorubicin Elucidated by Metabolic Profiling in Ovo. In Metabolites. 2020Jun;10:268. DOI:10.3390/metabo10070268.
   PubMed Web of Science ®Google Scholar
• Molneaux SM, Gross MI, Bromley SD, et al., inventorsTreating or preventing cancer, immunological disease, or chronic infection involves conjointly administering glutaminase inhibitor and immuno-oncology therapeutic agent patent US10940148B2. 2021.
   Google Scholar
• Coffey GL, Ehrlich J, Fisher MW, et al. 6-Diazo-5-oxo-L-norleucine, a new tumor-inhibitory substance I. Biologic studies. Antibiot Chemother. 1956 1956;6(8):487–497
   Google Scholar
• Stock CC, Reilly HC, Buckley SM, et al. Azaserine, a new tumour-inhibitory substance; studies with Crocker mouse sarcoma 180. Nature. 1954 1954 Jan;173(4393):71–72.
   PubMed Web of Science ®Google Scholar
• Ahluwalia GS, Grem JL, Hao Z, et al. METABOLISM AND ACTION OF AMINO-ACID ANALOG ANTICANCER AGENTS. Pharmacol Ther. 1990;46(2):243–271.
   PubMed Web of Science ®Google Scholar
• Robinson MM, McBryant SJ, Tsukamoto T, et al. Clinical development of metabolic inhibitors for oncology. Biochem J. 2007 Sep 15;406(3):407–414.
   PubMedGoogle Scholar
• Lemberg KM, Gori SS, Tsukamoto T, et al. Clinical development of metabolic inhibitors for oncology. J Clin Investig. 2022 Jan;132: 1.
   Web of Science ®Google Scholar
• Slusher B, Rais R, Majer P, et al., inventorsNovel glutamine antagonists and uses thereof patent WO2019071110A1. 2019.
   Google Scholar
• Slusher B, Rais R, Majer P, et al., inventorsProdrugs of glutamine analogs patent US2021206787A1. 2021.
   Google Scholar
• Li R, Ma C, Lian Z, et al., inventorsNovel glutamine analogs patent WO2022022612A1. 2022.
   Google Scholar
• Li R, Ma C, Lian Z, et al., inventorsNew 2-hydroxy-N-(2-oxoethyl)acetamide compound used as medicament in pharmaceutical composition for treating cancer patent WO2022078416A1. 2022.
   Google Scholar
• Li R, Ma C, Lian Z, et al., inventorsNew hydroxymethanediazonium-containing compound used in pharmaceutical composition for treating cancer in subject patent WO2022078462A1. 2022.
   Google Scholar
• Liu Z, Zheng M, Xu H, et al., inventorsNew prodrug of 6-diazo-5-oxo-L-norleucine compound used in preparation of drug for treating tumor patent CN114805138. 2022.
   Google Scholar
• Bian J, Li Z, Shen C, et al., inventorsNQO1 activated type 6-diazo-5-oxo-L-norleucine prodrug and preparation method and application thereof patent CN113461563 2021.
   Google Scholar
• McDermott LA, Iyer PC, Cerione R, et al., inventorsGlutaminase inhibitors patent US10245254B2. 2019.
   Google Scholar
• Zimmermann SC, Duvall B, Tsukamoto T. Recent Progress in the Discovery of Allosteric Inhibitors of Kidney-Type Glutaminase. J Med Chem. 2019 Jan;62(1):46–59.
   PubMed Web of Science ®Google Scholar
• Xu X, Meng Y, Li L, et al. Overview of the Development of Glutaminase Inhibitors: achievements and Future Directions. J Med Chem. 2019 Feb;62(3):1096–1115.
   PubMed Web of Science ®Google Scholar
• Liui C, Xiang Y, Cao J, et al., inventorsNew cycloalkylcarboxamide derivatives are glutaminase 1 inhibitors for preparing medicament for preventing or treating tumor or cancer patent CN114560855. 2022.
   Google Scholar
• Liui C, Xiang Y, Cao J, et al., inventorsHeterocyclic, derivative method and use thereof patent CN114805346. 2022.
   Google Scholar
• Li Z, Bian J, Xu X, et al., inventorsNew substituted aromatic amine compound useful in pharmaceutical composition for preparing medicine for treating glutaminase 1 enzyme-mediated disease patent CN110746416. 2020.
   Google Scholar
• Liao Y, Lin J, Liu C, et al., inventorsNew thiadiazole derivatives are glutaminase-1 (GLS1) inhibitors useful in preparing medicine for treating GLS1 related diseases patent WO2020078350A1. 2020.
   Google Scholar
• Wang J, Zhang H. inventorsNew heterocyclic compounds useful as GLS1 inhibitor in medicament for treating patent WO2022122044A1. 2022.
   Google Scholar
• Ruan B, Ruan J. inventorsA thiadiazole or tetrazole structure containing oxygen family element of kidney glutaminase allosteric site of inhibitor patent CN109988124. 2019.
   Google Scholar
• Bian J, Li Z, Yuan X, et al., inventorsMacrocyclic glutaminase GLS1 inhibitor or its pharmaceutically usable salt, its preparation and use patent CN111440199. 2020.
   Google Scholar
• Xu X, Wang JB, Wang M, et al. Structure-Enabled Discovery of Novel Macrocyclic Inhibitors Targeting Glutaminase 1 Allosteric Binding Site. J Med Chem. 2021 Apr;64(8):4588–4611.
   PubMed Web of Science ®Google Scholar
• Ruan B, Ruan J. inventorsCompounds targeting the renal glutaminase variable configuration site and Applications patent CN110396089. 2019.
   Google Scholar
• Kim C, Lee J, Park MS. Synthesis of new diorganodiselenides from organic halides: their antiproliferative effects against human breast cancer MCF-7 cells. Arch Pharm Res. 2015 May;38(5):659–665.
   PubMed Web of Science ®Google Scholar
• GF S. inventorGlutaminase inhibitors patent US2019309017A1. 2019.
   Google Scholar